(Q34510966)

2 August 2017

1 reference

title

Treatment options for visceral leishmaniasis (English)

1 reference

2 August 2017

main subject

visceral leishmaniasis

1 reference

Margriet den Boer

1

1 reference

2 August 2017

Robert N Davidson

series ordinal

2

1 reference

2 August 2017

publication date

1 April 2006

1 reference

Expert Review of Anti-infective Therapy

2 August 2017

published in

1 reference

2 August 2017

volume

4

1 reference

2 August 2017

issue

2

1 reference

2 August 2017

page(s)

187-197

1 reference

Leishmaniasis. Public health aspects and control

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.187

Kala-azar--progress against a neglected disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.187

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.187

The increase in risk factors for leishmaniasis worldwide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.187

Leishmaniasis: current situation and new perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.187

Emergence or re-emergence of visceral leishmaniasis in areas of Somalia, north-eastern Kenya, and south-eastern Ethiopia in 2000-01.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.187

Royal Society of Tropical Medicine and Hygiene joint meeting with Médecins Sans Frontières at Manson House, London, 20 March 2003: field research in humanitarian medical programmes. Médecins Sans Frontières interventions against kala-azar in the Sud

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.187

Leishmaniasis in Sudan. Visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.187

Leishmania/HIV co-infections: epidemiology in Europe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.187

Epidemic visceral leishmaniasis in southern Sudan: treatment of severely debilitated patients under wartime conditions and with limited resources

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.187

The epidemic of visceral leishmaniasis in western Upper Nile, southern Sudan: course and impact from 1984 to 1994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.187

Progress in the treatment of a neglected infectious disease: visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.187

Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.187

The immune response to Leishmania: mechanisms of parasite control and evasion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.187

Visceral leishmaniasis and HIV in Tigray, Ethiopia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.187

Post-kala-azar dermal leishmaniasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.187

Drug resistance in Indian visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.187

Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.187

Sodium stibogluconate cardiotoxicity and safety of generics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.187

A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.187

Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.187

Conflict and kala-azar: determinants of adverse outcomes of kala-azar among patients in southern Sudan

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.187

In vivo activity of paromomycin against susceptible and multidrug-resistant Mycobacterium tuberculosis and M. avium complex strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.187

The sensitivity of Leishmania species to aminosidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.187

Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.187

A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.187

Epidemic visceral leishmaniasis in Sudan: a randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.187

A policy for leishmaniasis with respect to the prevention and control of drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.187

Advances in the treatment of leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.187

Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.187

Liposomal amphotericin B (AmBisome) in the treatment of complicated kala-azar under field conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.187

Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.187

Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.187

The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.187

Oral miltefosine for Indian visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.187

Trial of oral miltefosine for visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.187

Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.187

Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.187

Clinical status of agents being developed for leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.187

Unseen Kala-azar deaths in south Sudan (1999-2002).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.187

Advances in leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.187

HIV and the transmission of Leishmania

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.187

In vitro and in vivo interactions between miltefosine and other antileishmanial drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.187

21 January 2018

Identifiers

DOI

10.1586/14787210.4.2.187

1 reference

2 August 2017

1 reference